Peninsula Pharmaceuticals

company

About

A bio­pharmaceuti­cal company focused on the devel­opment and com­mer­cializa­tion of antibi­otics.

  • 11 - 50

Details

Last Funding Type
Series B
Last Funding Money Raised
$22.10M
Industries
Biopharma,Biotechnology,Health Care,Health Diagnostics,Medical
Founded date
Jan 1, 2001
Number Of Employee
11 - 50
Operating Status
Active

Peninsula Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the licensing, development, and commercialization anti-infective therapies for the treatment of patients with life-threatening infections for the North American and European markets.



Peninsula's lead product candidate, doripenem, is a broad-spectrum antibiotic and a new member of the carbapenem class of beta-lactam antibiotics. Peninsula is currently evaluating doripenem in six Phase III clinical trials. In addition, doripenem received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of nosocomial pneumonia, including ventilator-associated pneumonia (VAP).



Peninsula Pharmaceuticals was acquired by Johnson & Johnson, a global manufacturer of health care products, as well as a provider of related services, for the consumer, pharmaceutical, and medical devices and diagnostics markets.



Peninsula Pharmaceuticals, Inc. is a privately held biopharmaceutical company focused on developing and commercializing antibiotics to treat life-threatening infections.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$22.10M
Peninsula Pharmaceuticals has raised a total of $22.10M in funding over 2 rounds. Their latest funding was raised on Oct 28, 2002 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Oct 28, 2002 Series B $22.10M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Peninsula Pharmaceuticals is funded by 1 investors. Sears Capital Management are the most recent investors.
Investor Name Lead Investor Funding Round
Sears Capital Management Series B